Lyell Therapeutics is a late-stage clinical cell therapy company developing next-generation autologous CAR T-cell therapies designed to treat hematologic malignancies and solid tumors by engineering patients' own immune cells with proprietary CAR constructs and manufacturing protocols. The company's lead program, rondecabtagene autoleucel, is a dual-targeting CD19/CD20 CAR T-cell therapy for relapsed/refractory large B-cell lymphoma that enriches for naïve and central memory T cells to enhance durability and anti-tumor activity, with pivotal clinical trials underway in late-line and second-line settings. Lyell operates a cGMP-compliant manufacturing facility in Washington state with capacity to produce over 1,200 CAR T-cell doses annually and monetizes through clinical development of its proprietary cell therapies, which target large addressable markets in oncology where approved CAR-T treatments are generating substantial revenue and demonstrating strong prescription switching based on improved efficacy and safety profiles.